PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2023 /PRNewswire/ — Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the preclinical anti-tumor efficacy and safety results of [¹⁷⁷Lu]Lu-TST001 have been published on European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI). In this preclinical studies, [¹⁷⁷Lu]Lu-TST001 demonstrated significant antitumor efficacy with acceptable toxicity. It exhibits strong potential for clinical translation, providing a new promising treatment option for CLDN18.2-overexpressing tumors, including gastric cancer.

This research was conducted in collaboration between Transcenta and the team of Professor Hua Zhu from Beijing Cancer Hospital. In this study, a [¹⁷⁷Lu]Lu-TST001 radionuclide antibody conjugate was developed that targets CLDN18.2 using a DOTA-TST001 as a precursor and is labeled with ¹⁷⁷Lu, a therapeutic radionuclide. The clear molecular imaging, favorable biodistribution, and pharmacokinetics of [¹⁷⁷Lu]Lu-TST001 were validated in a mouse xenograft GC model. Moreover, this study explored the short-term therapeutic efficacy of [¹⁷⁷Lu]Lu-TST001 radioimmunotherapy (RIT) against CLDN18.2-positive tumors and determined the optimal therapeutic dose in a GC tumor model. Safety under the treatment dose of the probe was also examined. Significant therapeutic effects with acceptable short-term toxicity were achieved in the mouse model.

“The study represents the first application of the therapeutic radionuclide [¹⁷⁷Lu]Lu-labeled CLDN18.2-targeting antibody TST001. This radionuclide antibody conjugate demonstrates great potential as an RIT drug for clinical application, which may offer a promising new treatment option for CLDN18.2-overexpressing tumors, such as gastric cancer, pancreatic cancer, esophageal cancer, and lung cancer, leading to improved survival outcomes.” said Prof. Hua Zhu from Beijing Cancer Hospital.

“Compared to localized gastric cancer, advanced metastatic gastric cancer often cannot be cured by chemotherapy or external radiation alone. In such cases, targeted RIT provides an opportunity to deliver radiation selectively to disease sites in patients with metastases, regardless of disease stage, offering a potential clinical treatment strategy for advanced tumor patients. We look forward to continuing our work with Prof Zhu and his team in an effort to bring [¹⁷⁷Lu]Lu-TST001 radionuclide antibody conjugate to patients in the near future.” said Dr. Xueming Qian, CEO of Transcenta.

About Osemitamab (TST001)

Osemitamab (TST001) is a high affinity humanized anti-CLDN18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (“ADCC”). It has shown potent anti-tumor activities in tumor xenograft models. Osemitamab (TST001) is the second most advanced CLDN18.2 targeting antibody being developed globally. Osemitamab (TST001) was generated using Transcenta’s Immune Tolerance Breaking Technology (IMTB) platform. Osemitamab (TST001) kills CLDN18.2 expressing tumor cells by mechanisms of ADCC. Leveraging advanced bioprocessing technology, the fucose content of Osemitamab (TST001) was significantly reduced during the production, which further enhanced NK cells mediated ADCC activity of Osemitamab (TST001). Clinical trials for Osemitamab (TST001) are ongoing in the U.S. and China (NCT05190575, NCT04396821, NCT04495296, NCT05608785 / CTR20201281). Osemitamab (TST001) was granted Orphan Drug Designation in the U.S. by FDA for the treatment of patients with gastric or gastroesophageal junction (G/GEJ) and pancreatic cancer.

About Transcenta Holding Limited

Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Princeton, US and in Beijing, Shanghai and Guangzhou of China, and External Partnering Center in Boston and Los Angeles, US. Transcenta has also initiated the construction of the Group Headquarters and the second high-end biopharmaceutical facility with ICB as its core technology in Suzhou Industrial Park. Transcenta is developing 13 therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

For more information, please visit www.transcenta.com and https://www.linkedin.com/company/transcenta. 

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Transcenta, are intended to identify certain of such forward-looking statements. Transcenta does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Transcenta with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Transcenta’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Transcenta’s competitive environment and political, economic, legal and social conditions.

Transcenta, the Directors and the employees of Transcenta assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

Transcenta and Osemitamab are trademarks of Transcenta Holding Limited. All other brands and product names may be trademarks and/or registered trademarks of their respective owners.

 

View original content:https://www.prnewswire.com/news-releases/transcenta-announces-the-publication-of-preclinical-results-of-177lulu-tst001-radionuclide-antibody-conjugate-as-potential-novel-treatment-option-for-metastatic-gastric-cancer-in-the-european-journal-of-nuclear-medicine-and-mole-302013860.html

SOURCE Transcenta Holding Limited

Featured image: Megapixl © Foxaon

Disclaimer